CTIS2024-511961-12-00进行中（未招募）1 期
Adaptative, multicenter, randomized, double-blind, parallel-group, placebo controlled, clinical trial, on the efficacy and tolerability of different escalating doses of intra-articular clodronate in patients with painful knee osteoarthritis - SPA-S-899-01-21
Spa Societa Prodotti Antibiotici S.p.A.0 个研究点目标入组 296 人开始时间: 2024年6月17日最近更新:
适应症
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 296
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 65+（—）
- 性别
- All
入选标准
- •Female and male patients aged 50 up to 75 years at the signature of informed consent form (ICF)., Diagnosis of knee OA according to the American College of Rheumatology, confirmed by Rx during the screening (a Rx performed in the last three (3) months before Screening Visit is accepted)., Kellgren-Lawrence radiographic score between 2 and 3 degrees in the tibiofemoral joint., Symptomatic knee OA (pain) since at least 6 months with a knee pain (VAS) ranging between 40 and 80 mm at Screening visit (the figure should be confirmed at Baseline)., Female patients of childbearing potential must have a negative pregnancy test before each treatment and during the Visit 5 – Week 4 and they must use adequate methods of contraception throughout the course of the study., A signed ICF by the patient after exhaustive study discussion with the investigators.
排除标准
- •BMI > 35 kg/m2 (Class II obesity)., Any treatment with denosumab in the 12 months before Baseline., Any treatment with paracetamol in the twelve (12) hours before Baseline., Any knee surgery in the past or knee arthroplasty., Any diagnostic or surgical arthroscopy of the knee in the six (6) months before Baseline., Any jaw osteonecrosis in the last twenty-four (24) months before Baseline or at a risk of jaw osteonecrosis., Any known hypersensitivity to the drug in the study and to its excipients or other bisphosphonates, and any hypersensitivity to paracetamol (rescue drug)., Any participation in a clinical study in which the last administration of the investigational medicinal product was within two (2) weeks before consenting to study participation (i.e. signing ICF)., Inadequate organ function defined by the following laboratory parameters: Absolute Neutrophil Count (ANC) < 1500/^l ; Haemoglobin (Hb) < 9 g/dl (< Hb 5.6 mmol/L) ; Platelet Count < 100.000/^l ; Serum Creatinine > 1.5 x ULN or eGFR < 60 mL/min (as per Cockroft-Gault formula) ; ALT or AST > 1.5 x ULN ; Serum Total Bilirubin > 1.5 x ULN, Pregnant or breastfeeding women, or women planning to become pregnant during the study., Any positive or suspected history of alcoholism or drug use., Joint instability due to other reasons than knee OA, such as f.i. algo dystrophic syndrome, either partial or complete rupture of internal / externals ligaments, kneecap instability, etc., Clinically significant (i.e.) gastrointestinal, renal, hepatic, pulmonary, cardiovascular or neurological disease that could interfere with the outcome of the study or the patient’s ability to comply with study requirements., Patients unwilling or unable to comply with the protocol., Otherwise located lower limb pain, such as hip pain., Other musculoskeletal disorders related to the target knee., Any treatment with IA drugs in the last three (3) month before Day 0- Baseline (including any formulation of corticosteroids, or hyaluronic acid injections)., Corticosteroid use by any systemic route, and hyaluronic acid injections or in-tra-articular corticosteroids for any other joint in the previous month will be not permitted., Any treatment with systemic non-steroidal anti-inflammatory drugs (NSAIDs) in the week before Baseline, or any steroid anti-inflammatory drugs and chon-droprotective drugs in the thirty (30) days before Baseline., Any treatment with systemic bisphosphonates in the last twelve (12) months before Baseline., Any treatment with glucosamine or chondroitin sulfate, diacerein and matrix metalloproteinase (MMP) inhibitors in the 4 weeks before Baseline.
研究者
相似试验
招募中
1 期
Clinical trial to assess the efficacy and tolerability of several escalating doses of clodronate, in patients with painful knee osteoarthritisPatients with painful knee osteoarthritisMedDRA version: 21.1Level: LLTClassification code 10029877Term: OA kneeSystem Organ Class: 100000004859EUCTR2021-003124-33-ITSPA-SOCIETÀ PRODOTTI ANTIBIOTICI S.P.A.296
进行中（未招募）
1 期
Rivaroxaban versus Aspirin in secondary prevention of stroke and prevention of systemic embolism in patients with recent embolic stroke of undetermined source (ESUS)Embolic stroke of undetermined source (ESUS)MedDRA version: 19.0Level: PTClassification code 10014498Term: Embolic strokeSystem Organ Class: 10029205 - Nervous system disordersEUCTR2013-000768-27-HUBayer AG7,000
进行中（未招募）
1 期
Rivaroxaban versus Aspirin in secondary prevention of stroke and prevention of systemic embolism in patients with recent embolic stroke of undetermined source (ESUS)EUCTR2013-000768-27-GRBayer HealthCare AG7,000
进行中（未招募）
1 期
Rivaroxaban versus Aspirin in secondary prevention of stroke and prevention of systemic embolism in patients with recent embolic stroke of undetermined source (ESUS)Embolic stroke of undetermined source (ESUS)MedDRA version: 17.0Level: PTClassification code 10014498Term: Embolic strokeSystem Organ Class: 10029205 - Nervous system disordersEUCTR2013-000768-27-SEBayer HealthCare AG7,000
进行中（未招募）
1 期
Rivaroxaban versus Aspirin in secondary prevention of stroke and prevention of systemic embolism in patients with recent embolic stroke of undetermined source (ESUS)Embolic stroke of undetermined source (ESUS)MedDRA version: 18.1 Level: PT Classification code 10014498 Term: Embolic stroke System Organ Class: 10029205 - Nervous system disordersEUCTR2013-000768-27-PTBayer HealthCare AG7,213